1. Dolgin, E., Nat. Biotechnol., 2018, vol. 36, no. 12, p. 1125. https://doi.org/10.1038/nbt1218-1125
2. Hennrich, U. and Kopka, K., Pharmaceuticals, 2019, vol. 12, no. 3, p. 114. https://doi.org/10.3390/ph12030114
3. Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer. www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer. Accessed August 1, 2022.
4. Baudhuin, H., Cousaert, J., Vanwolleghem, P., Raes, G., Caveliers, V., Keyaerts, M., Lahoutte, T., and Xavier, C., Pharmaceuticals, 2021, vol. 14, no. 5, p. 448. https://doi.org/10.3390/ph14050448
5. Mu, L., Hesselmann, R., Oezdemir, U., Bertschi, L., Blanc, A., Dragic, M., Löffler, D., Smuda, C., Johayem, A., and Schibli, R., Appl. Radiat. Isot., 2013, vol. 76, p. 63. https://doi.org/10.1016/j.apradiso.2012.07.022